TY - JOUR AU - Schmid, P; Rugo, H S; Adams, S TI - IMpassion130 Investigators. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial JO - Lancet Oncol VL - 21 PY - 2020 DO - 10.1016/S1470-2045(19)30689-8 L3 - PubMed-ID: 31786121 SP - 44 EP - 59 N1 - et al. ER -